UK markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.4900+0.0100 (+0.40%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 200.19M
Enterprise value 49.75M
Trailing P/E 11.63
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)46.53
Price/book (mrq)0.97
Enterprise value/revenue 12.65
Enterprise value/EBITDA -0.71

Trading information

Stock price history

Beta (5Y monthly) 0.56
52-week change 3-48.71%
S&P500 52-week change 3-12.46%
52-week high 34.9300
52-week low 31.6800
50-day moving average 32.2710
200-day moving average 32.9327

Share statistics

Avg vol (3-month) 3204.3k
Avg vol (10-day) 3251.12k
Shares outstanding 583.41M
Implied shares outstanding 6N/A
Float 828.49M
% held by insiders 152.06%
% held by institutions 118.72%
Shares short (12 Jan 2023) 4252.21k
Short ratio (12 Jan 2023) 40.76
Short % of float (12 Jan 2023) 40.64%
Short % of shares outstanding (12 Jan 2023) 40.30%
Shares short (prior month 14 Dec 2022) 4321.66k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,923.79%

Management effectiveness

Return on assets (ttm)-23.13%
Return on equity (ttm)-39.69%

Income statement

Revenue (ttm)3.93M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-62.28M
EBITDA -73.86M
Net income avi to common (ttm)-73.28M
Diluted EPS (ttm)-0.9990
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)140.5M
Total cash per share (mrq)1.68
Total debt (mrq)2.48M
Total debt/equity (mrq)1.31
Current ratio (mrq)10.85
Book value per share (mrq)2.27

Cash flow statement

Operating cash flow (ttm)-73.99M
Levered free cash flow (ttm)-44.62M